• Explore /
  • Poster
  • / CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.

Abstract Poster

Authors

null

Markus H. Moehler

University Medical Center Mainz, Mainz, Germany

Markus H. Moehler , Yelena Yuriy Janjigian , Antoine Adenis , Jean-Sebastien Aucoin , Narikazu Boku , Ian Chau , James M. Cleary , Kynan Feeney , Fabio A. Franke , Guillermo Ariel Mendez , Michael Schenker , Mingshun Li , Erika Hitre , Felix Couture , Michalis Karamouzis , Pierre-Luc Etienne , Jaffer A. Ajani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02872116

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS192)

DOI

10.1200/JCO.2018.36.4_suppl.TPS192

Abstract #

TPS192

Poster Bd #

M6

Abstract Disclosures

Similar Posters

First Author: Markus H. Moehler

First Author: Yelena Yuriy Janjigian

First Author: Lin Shen

First Author: Lin Shen